title: Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
authors.affiliation: Department of Medicine, Queen Mary Hospital, Hong Kong, China.
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
authors.affiliation: Serviço de Hematologia, Centro Hospitalar Conde De S. Januario, Macau, China.
authors.forename: David
authors.initials: D
authors.lastname: Lopes
authors.affiliation: Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China.
authors.forename: Pek-Lan
authors.initials: PL
authors.lastname: Khong
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab
keywords: PD-1; hodgkin lymphoma; pembrolizumab; refractory